These data are consistent with our integrated understanding of the TO of INGREZZA and drug exposure concentrations observed from INGREZZA in pivotal clinical trials. The superior target engagement observed with INGREZZA may be related to its single high affinity metabolite, compared with AUSTEDO XR, which generates multiple metabolites, including those with lower VMAT2 affinity. SAN DIEGO, Jan. 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first ...

Core Insights - Neurocrine Biosciences presented a post-hoc analysis from the Phase 3 KINECT 4 study, showing that continuous treatment with INGREZZA (valbenazine) at a 40 mg dose for 48 weeks led to significant improvements in tardive dyskinesia (TD) symptoms [1][5][6] Study Findings - The KINECT 4 study demonstrated that 90% of participants who completed 48 weeks of treatment with INGREZZA 40 mg achieved a 50% improvement in the Abnormal Involuntary Movement Scale (AIMS) total score [5][6] - Efficacy was assessed through clinician- and patient-reported measures, with sustained improvements observed throughout the treatment period [4][6] - The analysis included 45 patients on the 40 mg dose and 11 patients who escalated to 80 mg before reducing back to 40 mg, showing similar therapeutic benefits [3][6] Safety and Tolerability - The safety profile of INGREZZA remained consistent with previous studies, with most treatment-emergent adverse events being mild to moderate [4][9] - Common side effects included sleepiness and tiredness, with no new safety concerns identified during the study [4][20] Treatment Flexibility - INGREZZA is unique as the only VMAT2 inhibitor that allows patients to start at a therapeutic dose without the need for titration, providing flexibility in dosing based on individual response and tolerability [2][10]